Loss of dCK activity is a bona fide mechanism of Cytarabine resistance in AML patients and model tumor cell lines10–17, leading to cross-resistance to various nucleoside analog pro-drugs13,18–20 requiring activation via phosphorylation. This evidence concerns the gene DCK and acute myeloid leukemia.